Nationwide survival benefit after implementation of first-line immunotherapy for patients with advanced nsclc—real world efficacy

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Nationwide survival benefit after implementation of first-line immunotherapy for patients with advanced nsclc—real world efficacy. / Mouritzen, Mette T.; Carus, Andreas; Ladekarl, Morten; Meldgaard, Peter; Nielsen, Anders W.M.; Livbjerg, Anna; Larsen, Jacob W.; Skuladottir, Halla; Kristiansen, Charlotte; Wedervang, Kim; Schytte, Tine; Hansen, Karin H.; Østby, Anne Cathrine; Frank, Malene S.; Lauritsen, Jakob; Sørensen, Jens B.; Langer, Seppo W.; Persson, Gitte F.; Andersen, Jon L.; Frary, Johanna M.C.; Drivsholm, Lars B.; Vesteghem, Charles; Christensen, Heidi S.; Bjørnhart, Birgitte; Pøhl, Mette.

In: Cancers, Vol. 13, No. 19, 4846, 2021.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Mouritzen, MT, Carus, A, Ladekarl, M, Meldgaard, P, Nielsen, AWM, Livbjerg, A, Larsen, JW, Skuladottir, H, Kristiansen, C, Wedervang, K, Schytte, T, Hansen, KH, Østby, AC, Frank, MS, Lauritsen, J, Sørensen, JB, Langer, SW, Persson, GF, Andersen, JL, Frary, JMC, Drivsholm, LB, Vesteghem, C, Christensen, HS, Bjørnhart, B & Pøhl, M 2021, 'Nationwide survival benefit after implementation of first-line immunotherapy for patients with advanced nsclc—real world efficacy', Cancers, vol. 13, no. 19, 4846. https://doi.org/10.3390/cancers13194846

APA

Mouritzen, M. T., Carus, A., Ladekarl, M., Meldgaard, P., Nielsen, A. W. M., Livbjerg, A., Larsen, J. W., Skuladottir, H., Kristiansen, C., Wedervang, K., Schytte, T., Hansen, K. H., Østby, A. C., Frank, M. S., Lauritsen, J., Sørensen, J. B., Langer, S. W., Persson, G. F., Andersen, J. L., ... Pøhl, M. (2021). Nationwide survival benefit after implementation of first-line immunotherapy for patients with advanced nsclc—real world efficacy. Cancers, 13(19), [4846]. https://doi.org/10.3390/cancers13194846

Vancouver

Mouritzen MT, Carus A, Ladekarl M, Meldgaard P, Nielsen AWM, Livbjerg A et al. Nationwide survival benefit after implementation of first-line immunotherapy for patients with advanced nsclc—real world efficacy. Cancers. 2021;13(19). 4846. https://doi.org/10.3390/cancers13194846

Author

Mouritzen, Mette T. ; Carus, Andreas ; Ladekarl, Morten ; Meldgaard, Peter ; Nielsen, Anders W.M. ; Livbjerg, Anna ; Larsen, Jacob W. ; Skuladottir, Halla ; Kristiansen, Charlotte ; Wedervang, Kim ; Schytte, Tine ; Hansen, Karin H. ; Østby, Anne Cathrine ; Frank, Malene S. ; Lauritsen, Jakob ; Sørensen, Jens B. ; Langer, Seppo W. ; Persson, Gitte F. ; Andersen, Jon L. ; Frary, Johanna M.C. ; Drivsholm, Lars B. ; Vesteghem, Charles ; Christensen, Heidi S. ; Bjørnhart, Birgitte ; Pøhl, Mette. / Nationwide survival benefit after implementation of first-line immunotherapy for patients with advanced nsclc—real world efficacy. In: Cancers. 2021 ; Vol. 13, No. 19.

Bibtex

@article{ec696c90a155461b9f58fddef752ea2b,

title = "Nationwide survival benefit after implementation of first-line immunotherapy for patients with advanced nsclc—real world efficacy",

abstract = "Background The selection of patients with non-small cell lung cancer (NSCLC) for immune checkpoint inhibitor (ICI) treatment remains challenging. This real-world study aimed to compare the overall survival (OS) before and after the implementation of ICIs, to identify OS prognostic factors, and to assess treatment data in first-line (1L) ICI-treated patients without epidermal growth factor receptor mutation or anaplastic lymphoma kinase translocation. Methods Data from the Danish NSCLC population initiated with 1L palliative antineoplastic treatment from 1 January 2013 to 1 October 2018, were extracted from the Danish Lung Cancer Registry (DLCR). Long-term survival and median OS pre-and post-approval of 1L ICI were compared. From electronic health records, additional clinical and treatment data were obtained for ICI-treated patients from 1 March 2017 to 1 October 2018. Results The OS was significantly improved in the DLCR post-approval cohort (n = 2055) compared to the pre-approval cohort (n = 1658). The 3-year OS rates were 18% (95% CI 15.6–20.0) and 6% (95% CI 5.1–7.4), respectively. On multivariable Cox regression, bone (HR = 1.63) and liver metastases (HR = 1.47), performance status (PS) 1 (HR = 1.86), and PS ≥ 2 (HR = 2.19) were significantly associated with poor OS in ICI-treated patients. Conclusion OS significantly improved in patients with advanced NSCLC after ICI implementation in Denmark. In ICI-treated patients, PS ≥ 1, and bone and liver metastases were associated with a worse prognosis.",

keywords = "Advanced lung cancer, Anti-PD-1, Cancer immunotherapy, Clinical prognostic factors, Danish registry, First-line treatment, Immune checkpoint inhibitors, Non-small cell lung cancer, Overall survival, Real-world evidence",

author = "Mouritzen, {Mette T.} and Andreas Carus and Morten Ladekarl and Peter Meldgaard and Nielsen, {Anders W.M.} and Anna Livbjerg and Larsen, {Jacob W.} and Halla Skuladottir and Charlotte Kristiansen and Kim Wedervang and Tine Schytte and Hansen, {Karin H.} and {\O}stby, {Anne Cathrine} and Frank, {Malene S.} and Jakob Lauritsen and S{\o}rensen, {Jens B.} and Langer, {Seppo W.} and Persson, {Gitte F.} and Andersen, {Jon L.} and Frary, {Johanna M.C.} and Drivsholm, {Lars B.} and Charles Vesteghem and Christensen, {Heidi S.} and Birgitte Bj{\o}rnhart and Mette P{\o}hl",

note = "Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2021",

doi = "10.3390/cancers13194846",

language = "English",

volume = "13",

journal = "Cancers",

issn = "2072-6694",

publisher = "M D P I AG",

number = "19",

}

RIS

TY - JOUR

T1 - Nationwide survival benefit after implementation of first-line immunotherapy for patients with advanced nsclc—real world efficacy

AU - Mouritzen, Mette T.

AU - Carus, Andreas

AU - Ladekarl, Morten

AU - Meldgaard, Peter

AU - Nielsen, Anders W.M.

AU - Livbjerg, Anna

AU - Larsen, Jacob W.

AU - Skuladottir, Halla

AU - Kristiansen, Charlotte

AU - Wedervang, Kim

AU - Schytte, Tine

AU - Hansen, Karin H.

AU - Østby, Anne Cathrine

AU - Frank, Malene S.

AU - Lauritsen, Jakob

AU - Sørensen, Jens B.

AU - Langer, Seppo W.

AU - Persson, Gitte F.

AU - Andersen, Jon L.

AU - Frary, Johanna M.C.

AU - Drivsholm, Lars B.

AU - Vesteghem, Charles

AU - Christensen, Heidi S.

AU - Bjørnhart, Birgitte

AU - Pøhl, Mette

PY - 2021

Y1 - 2021

N2 - Background The selection of patients with non-small cell lung cancer (NSCLC) for immune checkpoint inhibitor (ICI) treatment remains challenging. This real-world study aimed to compare the overall survival (OS) before and after the implementation of ICIs, to identify OS prognostic factors, and to assess treatment data in first-line (1L) ICI-treated patients without epidermal growth factor receptor mutation or anaplastic lymphoma kinase translocation. Methods Data from the Danish NSCLC population initiated with 1L palliative antineoplastic treatment from 1 January 2013 to 1 October 2018, were extracted from the Danish Lung Cancer Registry (DLCR). Long-term survival and median OS pre-and post-approval of 1L ICI were compared. From electronic health records, additional clinical and treatment data were obtained for ICI-treated patients from 1 March 2017 to 1 October 2018. Results The OS was significantly improved in the DLCR post-approval cohort (n = 2055) compared to the pre-approval cohort (n = 1658). The 3-year OS rates were 18% (95% CI 15.6–20.0) and 6% (95% CI 5.1–7.4), respectively. On multivariable Cox regression, bone (HR = 1.63) and liver metastases (HR = 1.47), performance status (PS) 1 (HR = 1.86), and PS ≥ 2 (HR = 2.19) were significantly associated with poor OS in ICI-treated patients. Conclusion OS significantly improved in patients with advanced NSCLC after ICI implementation in Denmark. In ICI-treated patients, PS ≥ 1, and bone and liver metastases were associated with a worse prognosis.

AB - Background The selection of patients with non-small cell lung cancer (NSCLC) for immune checkpoint inhibitor (ICI) treatment remains challenging. This real-world study aimed to compare the overall survival (OS) before and after the implementation of ICIs, to identify OS prognostic factors, and to assess treatment data in first-line (1L) ICI-treated patients without epidermal growth factor receptor mutation or anaplastic lymphoma kinase translocation. Methods Data from the Danish NSCLC population initiated with 1L palliative antineoplastic treatment from 1 January 2013 to 1 October 2018, were extracted from the Danish Lung Cancer Registry (DLCR). Long-term survival and median OS pre-and post-approval of 1L ICI were compared. From electronic health records, additional clinical and treatment data were obtained for ICI-treated patients from 1 March 2017 to 1 October 2018. Results The OS was significantly improved in the DLCR post-approval cohort (n = 2055) compared to the pre-approval cohort (n = 1658). The 3-year OS rates were 18% (95% CI 15.6–20.0) and 6% (95% CI 5.1–7.4), respectively. On multivariable Cox regression, bone (HR = 1.63) and liver metastases (HR = 1.47), performance status (PS) 1 (HR = 1.86), and PS ≥ 2 (HR = 2.19) were significantly associated with poor OS in ICI-treated patients. Conclusion OS significantly improved in patients with advanced NSCLC after ICI implementation in Denmark. In ICI-treated patients, PS ≥ 1, and bone and liver metastases were associated with a worse prognosis.

KW - Advanced lung cancer

KW - Anti-PD-1

KW - Cancer immunotherapy

KW - Clinical prognostic factors

KW - Danish registry

KW - First-line treatment

KW - Immune checkpoint inhibitors

KW - Non-small cell lung cancer

KW - Overall survival

KW - Real-world evidence

U2 - 10.3390/cancers13194846

DO - 10.3390/cancers13194846

M3 - Journal article

C2 - 34638329

AN - SCOPUS:85115874983

VL - 13

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 19

M1 - 4846

ER -

ID: 281161582